Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06637371 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
A Phase 1 study of Asthma, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 16
- Study locations
NCT06637371 is a Phase 1 study of Asthma that is actively recruiting participants, run by Amgen. The registered enrollment target is 124 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT06637371, a Phase 1 study of Asthma, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 691
Study Locations (16)
Other
- Algemeen Ziekenhuis Sint Maarten-Emmaus vzw - Mechelen
- VPD Heart and Lung Research Institute - Cambridge
- Chelsea and Westminster Hospital - London
- The Medicines Evaluation Unit - Manchester
Florida
- Translational Clinical Research LLC - Aventura
- Destiny Research Center - Palmetto Bay
Minnesota
- Mayo Clinic - Rochester
- Prism Research LLC dba Nucleus Network - Saint Paul
North Carolina
- University of North Carolina Clinical and Translational Research Center - Chapel Hill
- North Carolina Clinical Research - Raleigh
California
- Orange County Research Center - Lake Forest
Georgia
- ClinCept, LLC - Columbus
Massachusetts
- Brigham and Womens Hospital - Boston
Texas
- Endeavor Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2027-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06637371
The ClinicalTrials.gov registry entry for NCT06637371 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06637371 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06637371 about?
NCT06637371 is a clinical study titled "A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma". The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
What is the current status of trial NCT06637371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2024-10-16. Estimated completion is 2027-06-07.
What conditions does trial NCT06637371 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06637371?
The interventions under investigation include: Placebo (DRUG), AMG 691 (DRUG).
Who is sponsoring clinical trial NCT06637371?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06637371 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.